Catalyst Pharmaceutical Partners (CPRX)
Catalyst Pharmaceutical Partners Revenues
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these CPRX related companies
CPRX News
Notable 52-Week Highs and Lows of the Day 05/24: (LCC) (PETM) (DUK) High; (NTAP) (RIMM) (CPRX) Low
May 24, 2:14PM Street Insider
May 24, 2:14PM Street Insider
Catalyst Pharmaceutical Partners Prices Underwritten Offering; 6M Units at $0.80/Unit
May 24, 8:45AM Benzinga
May 24, 8:45AM Benzinga
Catalyst Pharma (CPRX) Shares Jump 20% as CPP-115 Safe, Well Tolerated Across All Doses
May 22, 8:10AM Street Insider
May 22, 8:10AM Street Insider
Catalyst Pharmaceutical (CPRX) Reports Encouraging Data from CPP-115 Phase Ia
May 22, 8:05AM Street Insider
May 22, 8:05AM Street Insider
Catalyst Pharmaceutical Partners Announces First Quarter 2012 Financial Results
May 16, 8:03AM GlobeNewswire
May 16, 8:03AM GlobeNewswire
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2011 Financial Results
Apr 02, 8:03AM GlobeNewswire
Apr 02, 8:03AM GlobeNewswire
$CPRX forms bearish "Descending Continuation Triangle" chart pattern. http://stks.co/31zj
about 67 days ago by RecogniaEvents
about 67 days ago by RecogniaEvents
Catalyst Pharmaceutical Partners to Present at 24th Annual ROTH Conference
Mar 06, 8:03AM GlobeNewswire
Mar 06, 8:03AM GlobeNewswire
Catalyst Pharmaceutical Partners to Present at Cowen and Company's 32nd Annual Health Care Conference
Feb 28, 8:03AM GlobeNewswire
Feb 28, 8:03AM GlobeNewswire
$GNOM, $ESTE, $CPRX CRWENewswire Stocks In Action - http://stks.co/2NpV
about 105 days ago by pakistock
about 105 days ago by pakistock
Catalyst Pharmaceutical Partners to Present CPP-115 Progress at the 2012 Epilepsy Pipeline Update Conference
Jan 31, 8:03AM GlobeNewswire
Jan 31, 8:03AM GlobeNewswire
Catalyst Pharma (CPRX) Investigational Drug CPP-115 Gets FDA Fast-Track Designation
Dec 20, 10:17AM Street Insider
Dec 20, 10:17AM Street Insider
$CPRX Announces FDA Designation of CPP-115 as Fast-Track Development Program
about 160 days ago by Benzinga
about 160 days ago by Benzinga
Catalyst Pharmaceutical Partners, Inc. Announces FDA Designation of CPP-115 as a Fast Track Development Program
Dec 20, 10:13AM GlobeNewswire
Dec 20, 10:13AM GlobeNewswire
Catalyst Pharm announces commencement of Phase I(a) safety study for CPP-115
Dec 13, 8:19AM theflyonthewall.com
Dec 13, 8:19AM theflyonthewall.com
Catalyst Pharmaceutical (CPRX) Commences CPP-115 Phase Ia Safety Study
Dec 13, 8:03AM Street Insider
Dec 13, 8:03AM Street Insider
Catalyst Pharmaceutical Partners, Inc. Announces Commencement of Phase I(a) Safety Study for CPP-115
Dec 13, 8:03AM GlobeNewswire
Dec 13, 8:03AM GlobeNewswire
Catalyst Pharmaceutical Partners Promotes Alicia Grande to Vice President and Chief Financial Officer
Dec 02, 8:03AM GlobeNewswire
Dec 02, 8:03AM GlobeNewswire
Catalyst Pharmaceutical Partners Announces Third Quarter 2011 Financial Results
Nov 15, 8:03AM GlobeNewswire
Nov 15, 8:03AM GlobeNewswire
Catalyst Pharmaceutical (CPRX) Names Richard P. Rieger as Vice President, Commercial Operations
Nov 14, 8:07AM Street Insider
Nov 14, 8:07AM Street Insider
$cprx highs of day . takes out yest highs 1.75 goes to 1.95 then ___ :)
about 356 days ago by danshep55
about 356 days ago by danshep55
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CPRX | 0.561 | -0.01 | -1.58% | 13.86M |
| CPRT | 27.06 | -0.18 | -0.66% | 3.523B |
| CPO | 52.23 | -0.06 | -0.11% | 3.986B |
| CPNO | 26.64 | +0.19 | +0.72% | 1.923B |
| CPN | 16.91 | -0.01 | -0.06% | 8.139B |
| CPLP | 7.54 | +0.03 | +0.40% | 523.05M |
| DDS | 69.49 | -0.32 | -0.46% | 3.436B |
| DDR | 13.89 | -0.11 | -0.79% | 3.851B |
| DDIC | 12.98 | -0.01 | -0.08% | 265.83M |
| DDG | 36.25 | +0.15 | +0.42% |
